Head-To-Head Review: Smith & Nephew SNATS (NYSE:SNN) vs. PURE Bioscience (OTCMKTS:PURE)

Smith & Nephew SNATS (NYSE:SNN) and PURE Bioscience (OTCMKTS:PURE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Smith & Nephew SNATS and PURE Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
PURE Bioscience	-109.59%	N/A	-321.74%

Institutional and Insider Ownership

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 35.6% of PURE Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Smith & Nephew SNATS and PURE Bioscience”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16 billion	2.03	$625.00 million	N/A	N/A
PURE Bioscience	$2.20 million	4.14	-$2.40 million	($0.03)	-2.33

Smith & Nephew SNATS has higher revenue and earnings than PURE Bioscience.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Smith & Nephew SNATS and PURE Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0	5	1	0	2.17
PURE Bioscience	0	0	0	0	0.00

Smith & Nephew SNATS currently has a consensus price target of $30.93, suggesting a potential upside of 5.25%. Given Smith & Nephew SNATS’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Smith & Nephew SNATS is more favorable than PURE Bioscience.

Volatility & Risk

Smith & Nephew SNATS has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, PURE Bioscience has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.

Summary

Smith & Nephew SNATS beats PURE Bioscience on 9 of the 11 factors compared between the two stocks.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

About PURE Bioscience

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.